Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

BACKGROUND: Bevacizumab (Bev) has gained acceptance as an active agent in the treatment of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who are re-treated with Bev after achieving a complete response to a Bev-containing regimen (BCR). Our primary objective was to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: McCann, Georgia A., Smith, Blair, Backes, Floor J., Rath, Kellie, Chacko, Simi, Salani, Ritu, Eisenhauer, Eric, Fowler, Jeffrey, Cohn, David, Copeland, Larry, O’Malley, David
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3886294/
https://ncbi.nlm.nih.gov/pubmed/22885866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.08.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars